Silver Book Fact

A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is better than the others.

MacLean C, Newberry S, Maglione M, McMahon M, et al. Systematic Review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of Internal Medicine. 2008; 148(3): 186-96. http://www.ncbi.nlm.nih.gov/pubmed/18087050

Reference

Title
Systematic Review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis
Publication
Annals of Internal Medicine
Publication Date
2008
Authors
MacLean C, Newberry S, Maglione M, McMahon M, et al.
Volume & Issue
Volume 148, Issue 3
Pages
186-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.